Objective: To develop and assess a new formulation of Ropinirole-loaded chitosan nanoparticles incorporated into an in-situ gel for treating Parkinson's disease (PD), focusing on its properties and therapeutic potential. Methods: Physicochemical properties, drug-excipient compatibility, and thermal behavior of the nanoparticles were characterized using FTIR and DSC analysis. These nanoparticles were combined with a poloxamer-based in-situ gelling solution for nasal delivery. The formulation's therapeutic efficacy was tested in haloperidol-induced PD Wistar rats. Results: Successful development of ropinirole-loaded chitosan nanoparticles with desired properties was achieved. Incorporating them into an in-situ gel enhanced administration ease and nasal cavity retention. In PD rat models, the formulation reduced brain lipid peroxidation and TBARS levels, with highest GHS content in the in-situ gel-treated groups. Improved motor coordination, especially with the in-situ gel formulation, was observed in the catalepsy test. Conclusion: The intranasal delivery of Ropinirole-loaded chitosan nanoparticles in an in-situ gel exhibits stability, mucus penetration, and potential blood-brain barrier permeation for PD treatment. These results indicate a promising avenue for developing patient-friendly PD therapies. Further research into intranasal RNP formulations could enhance therapeutic outcomes in PD management.